July 2026 Research Update

Across these studies, testing for changes in the MEFV gene was commonly used to support a diagnosis of familial Mediterranean fever (FMF), but genetic results did not always give a simple yes-or-no answer. Some groups had high rates of detectable MEFV variants among people already suspected of FMF, while large testing cohorts showed many people with no variant or only one copy of a variant, which can be harder to interpret. A separate clinic-based study highlighted that when symptoms look like other conditions (such as chronic hives), additional clinical clues and inflammation blood tests helped decide who needed deeper evaluation. [1] [2] [3]

In a prospective multicenter study in Egypt of 280 people clinically suspected of FMF, MEFV variants were detected in 93.6%, and the most common allele was E148Q. The authors noted that fever was less common than expected in this group, which fit with the idea that some people may have incomplete or non-febrile attacks, and they emphasized using both Tel-Hashomer and Eurofever/PRINTO clinical criteria alongside genetic testing in this population. [1]

A large retrospective testing dataset from Eastern and Southeastern Anatolia in Turkey (8,252 individuals referred for recurrent MEFV variant testing) showed that 60.4% had no detected variant on the tested panel, 28.2% had one variant, and 11.4% had more than one. The most frequent variants were M694V and E148Q, and many variant-positive results were in exon 10, but this study did not link results to confirmed FMF symptoms, highlighting that genetic frequencies in a tested population are not the same as a diagnosis. [2]

In a chronic urticaria (chronic hives) registry from a specialized clinic, autoinflammatory syndromes were ultimately diagnosed in 8 of 573 patients (1.4%), including 2 people diagnosed with FMF. In this setting, red-flag symptoms (such as joint pains, fatigue, and recurrent fevers) and abnormal inflammation tests (such as elevated C-reactive protein) helped guide who received further autoinflammatory testing and genetic evaluation, because chronic hives can sometimes overlap with systemic inflammatory conditions. [3]

One study focused on a different genetic testing challenge: low-level somatic mosaicism, where a disease-causing gene change may be present in only some cells and can be missed by standard tests. Using deep next-generation sequencing in 5,530 referrals to an autoinflammatory reference center, mosaic variants were found in 83 diagnosed patients (20.6%), mainly in conditions other than FMF (such as VEXAS and cryopyrin-associated periodic syndromes). This work mainly adds background about why some people with autoinflammatory symptoms may need more sensitive genetic methods when standard testing is negative. [4]

For patients and caregivers, these papers reinforce that FMF diagnosis and testing are usually a combination of symptom history, basic inflammation blood tests, and genetic results rather than a single test result. They also show why genetic results can be confusing in real life: some variants are common in certain regions or appear in people tested for many different reasons, and some inflammatory conditions may require more specialized testing approaches than standard panels. What remains uncertain from this group is how often specific genetic patterns directly predict a persons symptoms or long-term risks, because some datasets lacked detailed clinical follow-up. [1] [2] [3] [4]

These studies suggest that FMF severity in children is not explained by genetics alone, but certain gene patterns are repeatedly linked to tougher disease. Earlier symptom onset and having two disease-related changes in a key part of the MEFV gene (exon 10) were tied to more frequent or longer attacks and higher inflammation on blood tests, while some children with a single change had milder illness. [5] [6]

In a single-center French cohort that used data-driven clustering (an exploratory way to group patients by their overall pattern of symptoms and test results), five distinct clinical subgroups were identified, ranging from very mild to severe disease needing higher treatment intensity. Severe subgroups were enriched in girls with early onset and M694V homozygosity, and the same genotype could appear in more than one clinical subgroup, showing that genotype alone did not fully predict severity. [5]

In a pediatric study from Duhok, Iraq, exon-10 mutations (especially M694V and M680I, when present as two disease-related copies) were linked to earlier onset, more frequent and longer attacks, and higher inflammation markers like erythrocyte sedimentation rate and C-reactive protein. Children carrying only the E148Q change tended to have milder disease, and parental relatedness was linked to a higher chance of having two pathogenic exon-10 changes. [6]

For families, these results help explain why two children with FMF can have very different day-to-day illness even if they share parts of the same genetic background: severity seems to reflect a mix of genetics, age at first symptoms, and broader symptom patterns. This is most useful as background context for understanding risk patterns in groups of patients; it does not reliably predict how severe any one child will be, especially because one study was exploratory and single-center and the other was cross-sectional. Both studies also reported no amyloidosis during their observation periods, so they cannot clarify which children are most at risk for that long-term complication. [5] [6]

Across these papers, treatments that block the interleukin-1 (IL-1) inflammation pathway (anakinra and canakinumab) are described as the main options when colchicine is not enough. Real-world registry data suggest many people achieve strong control on canakinumab over time, while a survey shows there is no single standard approach for reducing or stopping anakinra after remission. One case report highlights that ongoing hidden inflammation can matter even when common blood tests look normal, especially when kidney complications are present. [7] [8] [9]

In a real-world international registry of 158 people with familial Mediterranean fever (FMF) treated with canakinumab, complete control of both symptoms and inflammation blood markers was reported in 45.6% by 3 months and 58.6% by 12 months, with 55.2% at last follow-up. More than 80% had complete absence of clinical symptoms at each timepoint, and inflammation markers were reported to normalize by 3 months. People who reached complete control early (by 3 months) were more likely to achieve and maintain complete control later, and stopping canakinumab for lack of effect was reported as rare (6% or less). [7]

A survey of 81 pediatric rheumatologists (mostly in Turkiye) described how anakinra is used for colchicine-resistant FMF in routine care. Clinicians reported similar patterns for starting anakinra and checking response within the first month, but there was wide variation in how they reduced dosing over time, when they attempted to stop, and what they did if symptoms returned. After relapse following discontinuation, most clinicians (81.5%) reported restarting anakinra at the previously effective dose. [8]

One case report described a child with FMF who developed nephrotic syndrome from AA amyloidosis after a long delay in diagnosis and had a homozygous MEFV M694V gene change. The report noted that serum amyloid A (a blood marker linked to amyloid) stayed elevated even when C-reactive protein (a common inflammation test) became normal, and treatment was escalated from anakinra to canakinumab with follow-up ongoing. This single-patient report cannot predict what will happen for others, but it illustrates why different blood markers may be followed in some complicated cases. [9]

For patients and caregivers, this set of studies mainly provides background on how IL-1 blocking medicines are being used after colchicine does not fully control FMF. The canakinumab registry suggests that, in real-world practice, many people have no attacks and some also reach full normalization of inflammation blood tests over months, while the anakinra survey shows that decisions about tapering or stopping are not consistent across specialists. What remains uncertain from these papers is how best to choose between IL-1 medicines for a specific person, and what the safest and most effective long-term tapering or stopping strategy is, because the evidence here is observational (registry and survey) plus a single case report.

Across these papers, the main pattern is that long-term, low-level inflammation in Familial Mediterranean fever (FMF) may be measurable even between attacks, and it may relate to amyloidosis risk. One study focused on a composite blood marker built from a complete blood count, while another looked at large-scale hospital records of cardiac (heart) amyloidosis. Together, they support the idea that tracking inflammation over time matters for understanding amyloidosis risk, but they do not establish cause and effect or prove how best to use these measures in routine care. [10] [11]

In a retrospective study of 386 adults with FMF, a higher Pan-Immune-Inflammation Value (PIV), calculated from routine blood counts, was linked to a higher burden of MEFV gene mutations and to AA amyloidosis even during attack-free periods. People with amyloidosis had higher PIV levels than those without amyloidosis, and PIV separated these groups with moderate accuracy, similar to commonly used inflammation blood tests. This suggests PIV may reflect hidden (subclinical) inflammation that can continue between attacks, but the authors noted that prospective validation is needed. [10]

In a US National Inpatient Sample analysis of 23,119 hospitalizations with cardiac amyloidosis (2016 to 2020), FMF showed one of the strongest statistical links to having cardiac amyloidosis in the dataset. In-hospital death was more likely in patients who also had end-stage kidney disease, multiple myeloma, or older age. The authors cautioned that results may be limited by the accuracy of diagnosis coding in hospital records. [11]

For patients and caregivers, this group of studies mainly adds background about how researchers are trying to measure ongoing inflammation in FMF and how FMF appears in large datasets of amyloidosis, including heart amyloidosis. The blood-count based PIV is not yet a standard test for FMF; it is an example of a tool being studied to summarize inflammation during symptom-free periods, and it still needs confirmation over time and in other clinics. The hospital-record study supports that FMF can appear alongside cardiac amyloidosis in real-world data, but it cannot show why it happens, how often it occurs in the overall FMF population, or what an individual patient's risk is. [10] [11]

This months papers looked beyond attacks to ask whether familial Mediterranean fever (FMF) is linked to other health issues. Overall, the research points to measurable differences in blood-based cardiovascular risk markers, some signals about bone density in more severe pediatric disease, higher rates of allergic conditions in the wider population, and possible differences in gut bacteria. Most evidence here is cross-sectional (a snapshot in time), so it cannot prove what causes what. [12] [13] [14] [15] [16] [17]

In two pediatric studies, children with FMF had higher blood-based indices linked to cardiovascular risk than healthy controls, and these indices increased as FMF severity increased. In one of these studies, ultrasound thickness of the neck artery wall did not differ between FMF and controls, even though inflammation-related blood markers were higher. [12] [13]

Bone density results were mixed by severity and genetics in one pediatric study: the severe FMF group had lower spine bone density scores than mild/moderate FMF and controls, while standard bone metabolism lab tests did not differ. Bone density did not track with the cardiovascular risk indices, and bone density was lower in children with MEFV gene changes other than M694V. [12]

A country-wide population study reported that people with FMF had a higher prevalence of atopic (allergic) disorders than controls, arguing against the idea that FMF-related immune patterns protect against allergies. This study did not describe which specific allergic conditions drove the difference in the summary provided. [14]

Two studies focused on daily-life issues in children. One found teeth grinding (bruxism) was more common in children with FMF, while other dental measures (cavities, gum and plaque indices, saliva acidity, and parental dental anxiety) were similar to controls; within FMF, disease severity may affect how well children cooperate with dental exams. [15]

Another pediatric study assessed sleep quality and depressive symptoms during attack-free periods in children taking maintenance colchicine. In this sample, healthy controls scored worse than children with FMF on both sleep disturbance and depressive symptom scales, and within FMF, older age (especially adolescence) was linked to poorer sleep; FMF severity was not independently linked to these psychosocial scores. [16]

Finally, a very small adult pilot study (10 people with FMF and 10 controls) suggested that gut microbiota richness was lower in adults with FMF in remission taking colchicine, with higher levels of certain bacteria (including Eggerthella species). Because of the small size and because all patients were on colchicine, it is not clear whether these differences relate to FMF itself, treatment, diet, or other factors. [17]

For patients and caregivers, these studies mainly add background information about health areas that may sometimes overlap with FMF: heart and blood vessel risk markers, bone density (especially in more severe pediatric disease), allergic conditions, bruxism, sleep, mood, and gut bacteria patterns. Most results are early or observational, so they do not show that FMF directly causes these issues or that changing FMF care would change them. What remains uncertain includes how these findings vary by age, genetics, disease control over time, and medicines such as colchicine, and which measurements (if any) best predict future health problems.

This group of reports shows that familial Mediterranean fever (FMF) can sometimes show up in ways that resemble other conditions, which can delay recognition. The shared pattern was inflammation affecting muscles, the lining around the lungs or heart, the intestines, or the kidneys, with overlap that made the initial picture confusing. Because these are individual case reports, they illustrate possibilities rather than giving firm estimates of how often these situations happen. [18] [19] [20] [21]

In one patient with FMF, acute sarcoid myositis (a type of inflammatory muscle disease) looked like protracted febrile myalgia, an FMF-related syndrome with severe muscle pain and fever. The report emphasized that similar symptoms can come from different causes, which may change how clinicians interpret ongoing muscle pain and fever during an FMF course. [18]

Another report described a 65-year-old man with recurrent fever, pleural effusions, and pericarditis that evolved toward a constrictive pattern, where the heart lining can restrict filling. FMF was considered clinically even without genetic confirmation, and symptoms and inflammation markers improved rapidly after colchicine, after extensive testing did not identify another cause. [19]

Two reports linked unusual kidney and bowel presentations with consideration of atypical or genetically supported FMF. A 22-year-old woman with ulcerative colitis had persistent protein in the urine and microscopic blood; a kidney biopsy confirmed fibrillary glomerulonephritis, and protein in the urine and bowel inflammation improved after treatment that included colchicine. [20]

A 24-year-old man with ulcerative colitis and no Mediterranean ancestry presented with protracted febrile myalgia and was found to have an MEFV gene variant reported as autosomal dominant FMF. After early improvement with corticosteroids, six months of colchicine alone was reported alongside normalization of inflammatory markers and fecal calprotectin and resolution of a pericardial effusion, raising the question of whether some intestinal inflammation could be driven by MEFV-related inflammation in certain people. [21]

For patients and caregivers, these reports mainly serve as background information about how FMF can sometimes be mistaken for other inflammatory conditions (muscle disease, heart or lung lining inflammation, bowel disease, or kidney disease), including in people who are older or who do not fit the most typical ancestry patterns. Because the evidence here is limited to single-patient stories, it cannot show how common these situations are, or whether the same patterns would apply to others, but it does highlight why FMF can be challenging to recognize when symptoms fall outside the classic pattern.